Establishment of an mKate2-Expressing Cell Line for Non-Invasive Real-Time XXXX In Vivo Imaging.

@entity1 @entity0 @entity19 @entity5 @entity1311
PURPOSE: Non-invasive real-time in vivo imaging experiments using @entity19 as animal models have become crucial for understanding @entity5 development and treatment. In this study, we have developed and validated a new @entity0 cell line MDA-MB-435s that stably express a far-red fluorescence protein (mKate2) and that could serve as a highly valuable cell model for studying @entity0 detection and therapy using in vivo fluorescence imaging in @entity19 . PROCEDURES: The new cell line (MDA-MB-435s-mKate2) was constructed by plasmid transfection. The stability and sensitivity of mKate2, and the cell biological activities, were tested in vitro using different experimental approaches. For its potential use in @entity5 growth research and drug therapy in vivo, MDA-MB-435s-mKate2 was validated using the immunocompromised Balb/c @entity19 @entity5 model. In addition, the new cell line has been characterized as a luteinizing hormone-releasing hormone receptor (LHRHR) positive cell line. RESULTS: Firstly, MDA-MB-435s-mKate2 has shown a stable chromosomal integration of the amplified mKate2 gene and good fluorescence sensitivity for detection using a fluorescence reflectance imaging (FRI) device. Compared to its parental cell line, no significant difference in cell migration, proliferation, and clone formation was observed in vitro. Secondly, using the quantification of @entity5 -fluorescence surface area in live animals, we were able to monitor and detect the @entity5 progress or @entity5 inhibition rate (by @entity1311 treatment) non-invasively and in real-time. Furthermore, MDA-MB-435s-mKate2 has been positively tested for LHRHR; these findings open the possibility to use this cell line for future studies of @entity0 therapy based on LHRH analogs in vivo. CONCLUSION: In the present research, we have successfully built the @entity1 -mKate2 cell line that can be used as a suitable cell model for @entity0 therapy and anti- @entity5 drug evaluation by non-invasive fluorescence imaging in @entity19 .
